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Objectives:  Serum S100A8/S100A9 and S100A12 levels have been shown to be elevated in 
giant cell arteritis (GCA).  This study aimed to determine if levels of serum S100 proteins 
perform as markers in a comparable fashion to standard markers of disease activity in large-
vessel vasculitis. 
Methods: Serum samples were obtained from the Vasculitis Clinical Research Consortium 
(VCRC) Longitudinal Study of GCA and Takayasu’s arteritis (TAK).  A mixed effects model 
compared S100 proteins during active and inactive disease states.  Receiver operating 
characteristic curves compared models using S100 proteins to models using ESR and CRP. 
Results: There were 106 samples (50 during active disease) from patients with GCA and 32 
samples (16 during active disease) from patients with TAK.  In GCA, S100A8/S100A9 and 
S100A12 were significantly elevated during active disease (2150 ng/mL vs. 2020 ng/mL, p = 
0.003;150 ng/mL vs. 130ng/mL, p=0.016, respectively).  There were weak correlations between 
levels of S100 proteins and ESR or CRP.  A model including S100A8/S100A9, S100A12, ESR, 
and CRP was a better indicator of disease activity compared to ESR and CRP together.  In TAK, 
there were no significant differences between active and inactive disease for either the S100 
proteins or ESR/CRP. 
Conclusions: Serum levels of S100A8/S100A9 and S100A12 are elevated during active disease 
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Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are forms of large-vessel 
vasculitis characterized by similarities in histological changes as well as the distribution of vessel 
involvement.  Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are widely 
used clinical inflammatory markers in the assessment of disease activity in both GCA and TAK.  
However, there are limitations to the clinical use of these biomarkers.  In TAK, the ESR and 
CRP have been shown to be normal in up to 30% and 48%, respectively, of patients with 
clinically active disease (1, 2).  In GCA, the sensitivity of ESR and CRP for predicting a positive 
temporal artery biopsy is 84% and 87% respectively (3).  Furthermore, autopsy studies have 
suggested that smoldering large-vessel vasculitis can exist that is not recognized clinically (4).  A 
search for improved biomarkers is warranted.   
Calgranulins, including S100A8 (also known as calgranulin A, myeloid-related protein 
8), S100A9 (also known as calgranulin B, myeloid-related protein 14) and S100A12 (also known 
as calgranulin C, myeloid-related protein 6), are calcium binding proteins expressed during 
myeloid differentiation.  S100A8 and S100A9 are found in granulocytes, monocytes, and early 
differentiation stages of macrophages and form heterodimeric complexes in a calcium-dependent 
manner.  In contrast, S100A12 is more restricted to granulocytes.  Calgranulins are linked with 
the innate immune response, and upon release by myeloid cells serve as damage-associated 
molecular pattern molecules (DAMPs).  S100A12 is able to bind to and activate the receptor of 
advanced glycation end products (RAGE) expressed on vascular smooth muscle cells, 
mononuclear cells and endothelial cells and initiate a proinflammatory danger signal (5). 
Previous studies have shown that S100A8/S100A9 are useful markers for disease activity for 
various rheumatic diseases including oligoarticular and polyarticular juvenile rheumatoid 
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arthritis (JRA), ulcerative colitis,  systemic lupus erythematosus, reactive arthritis, and 
rheumatoid arthritis (6-11). 
Prior studies have also demonstrated the presence of S100A8/A9 and S100A12 in biopsy 
specimens in GCA and TAK patients.  In a Spanish cohort (12) of 35 temporal artery biopsies 
with active vasculitis it was demonstrated that S100A8/S100A9 complex can be identified in the 
adventitia and media of affected arteries, whereas S100A12 expression is found around the vasa 
vasorum of the adventitia.  In the same cohort, serum concentrations by ELISA of both 
S100A8/S100A9 and S100A12 were significantly higher in patients with giant cell arteritis than 
in healthy non-matched controls (12).  Moreover, gene expression profiles of temporal arteries 
from patients with GCA, revealed a significant increase in the gene expression of S100A8, 
S100A9, S100A12 as compared to control temporal arteries. Interestingly, the gene expression 
for these S100 proteins were significantly increased even when no inflammation was seen on 
temporal arteries of GCA patients suggesting that S100A8, S100A9 and S100A12 may play an 
early role in the inflammatory cascade (13).  In addition, S100 positive cells have been found to 
be prominent in the inflammatory infiltrate of the aortic wall of patients with TAK (14).   
This study is aimed to assess the association of S100 proteins with disease activity in two 
forms of large vessel vasculitis, GCA and TAK, and to determine the role of these markers in 






Serum samples were obtained from the Vasculitis Clinical Research Consortium (VCRC) 
Longitudinal Study of GCA and TAK.  The VCRC is an integrated group of academic medical 
centers, patient support organizations, and clinical research resources dedicated to conducting 
clinical research in different forms of vasculitis.  This study is in compliance with the 
Declaration of Helsinki and has been approved by the Cleveland Clinic institutional review 
board.   
All patients met either the modified American College of Rheumatology (ACR) criteria 
for GCA or the modified ACR criteria for TAK(15, 16).  There were a total of 106 samples from 
59 patients with GCA and 32 serum samples from 16 patients with TAK.  Physicians completed 
a physician global assessment (PGA) and Birmingham Vasculitis Activity Score version 1 
(BVAS1).  Active disease was defined as BVAS1 score greater than then 0 and a physician’s 
global assessment greater than 0.  The serum concentrations of S100A8/S100A9 heterodimers 
and S100A12 were measured by ELISA as described previously (12).   
A mixed effects model was used to compare average levels of S100A8/S100A9 or 
S100A12 in active and inactive disease states.  Actual modeling was done using measurements 
on the log scale and then estimates and confidence intervals were converted back onto the 
original measurement scale.  Estimated differences between active and inactive disease states 
therefore are represented by multiplicative factors.  Logistic regression models were used to 
predict disease state from marker levels.  Two separate models were fit, one involving the 
traditional measurements and the other the two S100 measurements.  For each model, the 
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inclusion of the spline terms was investigated using bootstrap validation, and as a result ESR was 
included as a cubic spline with 4 knots.  
The qualities of predictions of disease activity from these models using either the 
traditional measures (ESR and CRP) or the two new measurements (S100A8/S100A9 and 
S100A12) were assessed using receiver operating characteristic (ROC) curves and were based on 
the area under the curve (AUC).  Confidence intervals for AUC were produced using the 
DeLong approach.   
Correlations between the markers were described separately for the active disease and 
inactive disease states, to avoid potential effects on correlations due to repeated measurements on 
patients.  The type of correlation used for this was Kendall’s rank correlation tau.  All analyses 
were done using R software (version 2.15.1, Vienna, Austria).  A significance level of 5% was 





Giant Cell Arteritis 
Serum samples were obtained from 59 patients with GCA (Table 1).  The majority of 
patients were female (74.6%) and Caucasian (98.3%).  The average age at study registration was 
71 years old.  Forty-two patients (71%) had positive temporal artery biopsies diagnostic for 
GCA.  Forty-six (78%) patients had samples drawn during both active and inactive disease.  
 
Table 1: Baseline Patient Characteristics 
Factor N Statistic N Statistic
59 16
Positive TABa 42 71.2%
Sexa Female 44 74.6% 14 87.5%
Male 15 25.4% 2 12.5%
Racea
Asian 1 1.7% 1 6.3%
White 58 98.3% 15 93.8%
Age at enrollment (years)b 59 70.65±13.28 35.4±12.8
Age at visit Active 50 70.9(67.5,74.4)
 (by sample,years)bd Inactive 56 71.5(68.1,74.9)
Observation times 59 16
Active and Inactive 46 78.0% 14 87.5%
Both Active 1 1.7%
Just Active 2 3.4% 1 6.3%
Just Inactive 10 16.9% 1 6.3%
Medicationsa Active Inactive
Prednisone 84.0% 92.7% 75.0% 68.8%
  Duration (months)c 2 3 15 3.5
Aspirin 58.0% 66.4% 68.8% 68.8%
Azathioprine 0.0% 0.0% 12.5% 18.8%
Cyclophosphamide 2.0% 0.0% 0% 0%
Infliximab 0.0% 0.0% 12.5% 18.8%
Methotrexate 14.0% 23.6% 37.5% 50.0%
Mycophenolate 0.0% 0.0% 6.3% 0.0%
aPercentage; bMean±SD;cMedian;dp<0.001, TAB = temporal artery biopsy
Giant Cell Arteritis Takayasu's Arteritis
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There were significantly higher CRP serum levels during active (7.8 mg/L [IQR 3.0-
30.6]) compared with inactive disease (5.2 mg/L [IQR 3.0-8.5]) (p = 0.015) and there was a non-
significant trend toward a high ESR during active disease (26.5 mm/h [12-44] versus 15.5 mm/h 
[IQR 10-25]; p = 0.066).  Serum S100A8/A9 and S100A12 levels were measured on 50 samples 
during active disease and 56 samples during inactive disease.  The mean serum levels of 
S100A8/9 and S100A12 were both significantly higher during active disease compared with 
inactive disease; S100A8/9: 2150 ng/mL [IQR 1563,3665] vs. 2020 ng/mL [IQR 1355,2493], p = 
0.003; S100A12: 150 ng/mL [IQR 98,335] vs. 130ng/mL [IQR 60,213], p=0.016 (Table 2, 
Figure 1). 
Table 2: Summary of serum levels1 of tested biomarkers in inactive and active disease in 
patients with GCA 
       
  Inactive Disease Active Disease  
Biomarker Total 
Samples 
N Median [IQR] N Median [IQR] p-value 
ESR (mm/hr) 100 54 15.5 [10.2, 25] 46 26.5 [12.2, 43.8] 0.066 
CRP (mg/L) 94 50 5.2 [3, 8.5] 44 7.8 [3, 30.6] 0.015 
S100A8/9 
(ng/mL) 
106 56 2020 [1355, 2492.5] 50 2150 [1562.5, 3665] 0.003 
S100A12 
(ng/mL) 
106 56 130 [60, 212.5] 50 150 [98.2, 335] 0.016 
1Comparisons on log scale using linear mixed effects model. GCA=Giant cell arteritis, N=number 








Figure 1: Serum levels of S100A8/9 (MRP) (top) and S100A12 (A12) (bottom) 






An AUC of 0.73 was obtained from an ROC curve using the combination of ESR and 
CRP for the association with disease activity (as defined earlier).  Using a model with the 
combination of S100A8/9 and S100A12 an AUC of 0.61 was obtained.  A model using all the 
markers (ESR, CRP, S100A8/9, and S100A12) produced an AUC of 0.79 which was not 
significantly greater than models using only S100 proteins or traditional biomarkers (p=0.13) 
(Figure 2).  Accounting for repeated measurements, using a generalized estimating equations 




Figure 2: ROC curves for tested biomarkers as measures of disease activity in patients with giant 





There was a strong correlation between measurements of CRP and measurements of ESR 
during active disease.  Similarly, there was a strong correlation between S100A8/9 and S100A12 
measurements during active disease.  However, there were weak correlations between both ESR 
and CRP, and the S100 proteins.  Similarly, weak correlations were seen between the S100 
proteins and traditional biomarkers during inactive disease (Table 3).   
Takayasu’s Arteritis 
Table 3. Correlations between biomarkers in giant cell arteritis 
      Active Disease 
      CRP ESR S100A8/A9 S100A12 
 CRP - 
    ESR 0.56 - 
   S100A8/A9 0.03  0.01 - 
  S100A12 0.01 -0.02 0.75 - 
 
      Inactive Disease 
      CRP ESR S100A8/A9 S100A12 
 CRP - 
    ESR 0.35 - 
   S100A8/A9 -0.03 0.10 - 
  S100A12 0 0.11 0.66 - 






Serum samples were obtained from 16 patients with TAK (Table 1).  The majority of 
patients were female (87.5%) and Caucasian (93.8%).  The mean age when the serum was 
collected was 35 years old (range 19-65).  The mean CRP during active disease was 1.2 times 
that of inactive disease (6.20mg/L [95%CI 2.20, 17.56] vs. 5.12mg/L [2.41, 10.86], p=0.69).  
The mean ESR during active disease was 1.3 times that of inactive disease (16.43mm/h [95% CI 
8.62, 30.66] vs. 12.67mm/h [95% CI 7.41, 21.66], p=0.40).  There was a non-statistically 
significant increase in S100A8/9 levels during active disease compared to levels during inactive 
disease: 1028 ng/mL [95%CI 640, 1652] vs 843ng/mL [95%CI 536, 1327], p=0.38.  There were 
no differences in the S100A12 levels between active and inactive disease (86.8 ng/mL [95%CI 
50.2, 150.6] vs 85.1 ng/mL [47.9, 151.1], p=0.93) (Figure 1).  None of the biological markers 
(CRP, ESR, S100A8/9 nor S100A12) significantly correlated with disease activity in logistic 





Results of the present study demonstrate that circulating levels of S100A8/A9 and 
S100A12 are significantly higher in patients with GCA when the disease is active compared to 
when the disease is inactive.  However, compared to the traditional biomarkers ESR and CRP, 
the S100 proteins had weaker correlations with disease activity.  Furthermore, there was 
insufficient evidence that measurement of serum S100 proteins significantly provides additional 
clinical information when used in conjunction with traditional biomarkers.   
In TAK there was no significant association between serum S100 proteins levels and 
disease activity.  Similarly, there was a poor association between either ESR or CRP and disease 
activity, a finding consistent with prior reports (1, 2).  Although assembling 16 paired samples of 
during active/inactive disease is a moderately sized group for a study of such a rare disease, each 
of the measurements was associated with wide confidence intervals and the study may well have 
been underpowered to detect a clinically meaningful difference between S100 proteins during 
active and inactive disease.  
There are several strengths to this study.  First, patient samples were provided from a 
large registry to which multiple centers across the United States and Canada contribute.  Thus, 
the results of this study are likely generalizable to patients with GCA and TAK in North 
America.  Second, patient assessments were conducted prospectively, using standardized forms.  
Third, the S100A8/A9 and S100A12 samples were all tested in the same laboratory using similar 




There are limitations of this study to consider.  The majority of patients in the study were 
on some dose of prednisone when the serum was obtained which may have suppressed levels of 
the S100 proteins, CRP, and ESRs.  However, GCA is a sight threatening disease in which rapid 
onset of treatment with glucocorticoids is imperative to prevent permanent vision loss.  Thus the 
majority of patients with a suspicion of GCA are started on glucocorticoids even prior to 
obtaining confirmatory tests such as temporal artery biopsies.  The second limitation was that 
ESR and CRP are widely used markers for assisting in assessment of disease activity and each 
could have potentially biased the PGA score and resulted in overestimations of the association of 
these markers with disease activity.  Conversely, this bias could have led to an underestimation 
of the additional utility of measuring levels of S100 proteins.  The third limitation was that 29% 
of our GCA cohort was not biopsy proven; however, all met validated classification criteria for 
the diagnosis of GCA. 
This study provides insufficient evidence supporting use of serum S100A8/A9 and 
S100A12 levels in the assessment of disease activity in large-vessel vasculitis.  However, this is 
the first study to demonstrate a statistical difference between serum levels S100A8/A9 and 
S100A12 based on disease activity in GCA.  Prior studies from out group have demonstrated that 
gene expression of S100A8, S100A9 and S100A12 is increased in the temporal arteries of 
patients with GCA compared to controls (13), even in temporal arteries that did not show signs 
of inflammation, suggesting a role of these S100A proteins early in the inflammatory cascade.  
The exact role of S100 proteins in the pathogenesis of vasculitis remains unclear.  The role of 
S100A8/A9 and S100A12 as a diagnostic marker of GCA in “normal” temporal artery biopsies 
has yet to be explored.  This study also emphasizes that both ESR and CRP have limited utility 
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for the assessment of disease activity in large-vessel vasculitis and the need for development of 
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